Limits...
A randomized controlled study on the efficacy of a novel combination vaccine against enzootic pneumonia ( Mycoplasma hyopneumoniae ) and porcine Circovirus type 2 (PCV2) in the presence of strong maternally derived PCV2 immunity in pigs

View Article: PubMed Central - PubMed

ABSTRACT

Background: Mycoplasma hyopneumoniae (M. hyo) and Porcine Circovirus Type 2 (PCV2) are major pathogens that cause significant health problems in swine worldwide. Maternal derived immunity (MDI) has been suggested as a significant immediate defence factor for newborn piglets and may interfere with piglet’s vaccination-induced immunity. The study aimed to assess the efficacy of a novel combination vaccine (consisting of PCV2 subunits and inactivated M. hyo strain J), against PCV2 and M. hyo natural infection [Porcilis® PCV M Hyo (MSD Animal Health, Boxmeer, the Netherlands)], in the presence of strong maternally derived PCV2 immunity (antibody titre averaged 11.08 log2), under field conditions. The study was performed according to a controlled, randomized and blinded design in a Greek swine unit with Enzootic Pneumonia (EP) and subclinical PCV2 infection. In total, 600 healthy three-week-old suckling piglets were allocated randomly, either to treatment (vaccinated with the test product) or control group (injected with sterile buffered saline).

Results: Vaccination significantly reduced the severity of lung lesions at slaughter (lesions of cranio-ventral pulmonary consolidation) (P < 0.001). The overall mean lung lesion score (LLS) was 9.6 in the vaccinated group and 12.2 in controls. The level of PCV2 viraemia was significantly reduced in vaccinated pigs. Furthermore, 25 g higher average daily weight gain (ADWG) was observed during the finishing phase (P < 0.001) and 18 g greater ADWG overall (P < 0.001).

Conclusions: Results of LLS, PCV2 viremia and ADWG support the test product’s efficacy in the face of strong maternally derived PCV2 immunity.

No MeSH data available.


Related in: MedlinePlus

Representative findings of lung and pleuritis lesions in trial animals. Figure a: lung has normal appearance. Figures b and c: purple (b) and grey (c) consolidation located in cranial and middle lobes. In Fig. c the caudal lobes are also affected. Figure d: lung shows intense purple consolidation of the cranial, middle and caudal lobes. Figure e: in ventral view of the previous lung (d), lesions of bronchopneumonia are distributed in all lobes. Figure f: enzootic pneumonia complicated with Actinobacillus pleuropneumoniae infection accompanied by localized fibrous pleurisy (left caudal lobe). [a - c: Vaccinated group (Porcilis PCV M Hyo)] [d - f: Control group (Unisol)]
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC5384188&req=5

Fig4: Representative findings of lung and pleuritis lesions in trial animals. Figure a: lung has normal appearance. Figures b and c: purple (b) and grey (c) consolidation located in cranial and middle lobes. In Fig. c the caudal lobes are also affected. Figure d: lung shows intense purple consolidation of the cranial, middle and caudal lobes. Figure e: in ventral view of the previous lung (d), lesions of bronchopneumonia are distributed in all lobes. Figure f: enzootic pneumonia complicated with Actinobacillus pleuropneumoniae infection accompanied by localized fibrous pleurisy (left caudal lobe). [a - c: Vaccinated group (Porcilis PCV M Hyo)] [d - f: Control group (Unisol)]

Mentions: The primary parameter of LLS was significantly reduced in the vaccinated group when compared with the controls (Mixed model ANOVA P < 0.001). Table 2 summarizes results of LLS and pleuritis lesions among groups. The LLS was further “separated” into four categories [i.e. score = 0 (absent), score= > 0–5 (mild), score= > 5–10 (moderate), score > 10 (severe)]. The evaluation of this distribution showed that more than half of the control group cases were categorized in the fourth category, while less than 40% of the vaccinated group cases were in the same category (Fig. 3). Insignificant differences in the proportion of animals with pleuritis lesions were observed between the trial groups (P = 0.0759). Representative findings of lung and pleuritis lesions are presented in Fig. 4.Table 2


A randomized controlled study on the efficacy of a novel combination vaccine against enzootic pneumonia ( Mycoplasma hyopneumoniae ) and porcine Circovirus type 2 (PCV2) in the presence of strong maternally derived PCV2 immunity in pigs
Representative findings of lung and pleuritis lesions in trial animals. Figure a: lung has normal appearance. Figures b and c: purple (b) and grey (c) consolidation located in cranial and middle lobes. In Fig. c the caudal lobes are also affected. Figure d: lung shows intense purple consolidation of the cranial, middle and caudal lobes. Figure e: in ventral view of the previous lung (d), lesions of bronchopneumonia are distributed in all lobes. Figure f: enzootic pneumonia complicated with Actinobacillus pleuropneumoniae infection accompanied by localized fibrous pleurisy (left caudal lobe). [a - c: Vaccinated group (Porcilis PCV M Hyo)] [d - f: Control group (Unisol)]
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC5384188&req=5

Fig4: Representative findings of lung and pleuritis lesions in trial animals. Figure a: lung has normal appearance. Figures b and c: purple (b) and grey (c) consolidation located in cranial and middle lobes. In Fig. c the caudal lobes are also affected. Figure d: lung shows intense purple consolidation of the cranial, middle and caudal lobes. Figure e: in ventral view of the previous lung (d), lesions of bronchopneumonia are distributed in all lobes. Figure f: enzootic pneumonia complicated with Actinobacillus pleuropneumoniae infection accompanied by localized fibrous pleurisy (left caudal lobe). [a - c: Vaccinated group (Porcilis PCV M Hyo)] [d - f: Control group (Unisol)]
Mentions: The primary parameter of LLS was significantly reduced in the vaccinated group when compared with the controls (Mixed model ANOVA P < 0.001). Table 2 summarizes results of LLS and pleuritis lesions among groups. The LLS was further “separated” into four categories [i.e. score = 0 (absent), score= > 0–5 (mild), score= > 5–10 (moderate), score > 10 (severe)]. The evaluation of this distribution showed that more than half of the control group cases were categorized in the fourth category, while less than 40% of the vaccinated group cases were in the same category (Fig. 3). Insignificant differences in the proportion of animals with pleuritis lesions were observed between the trial groups (P = 0.0759). Representative findings of lung and pleuritis lesions are presented in Fig. 4.Table 2

View Article: PubMed Central - PubMed

ABSTRACT

Background: Mycoplasma hyopneumoniae (M. hyo) and Porcine Circovirus Type 2 (PCV2) are major pathogens that cause significant health problems in swine worldwide. Maternal derived immunity (MDI) has been suggested as a significant immediate defence factor for newborn piglets and may interfere with piglet&rsquo;s vaccination-induced immunity. The study aimed to assess the efficacy of a novel combination vaccine (consisting of PCV2 subunits and inactivated M. hyo strain J), against PCV2 and M. hyo natural infection [Porcilis&reg; PCV M Hyo (MSD Animal Health, Boxmeer, the Netherlands)], in the presence of strong maternally derived PCV2 immunity (antibody titre averaged 11.08 log2), under field conditions. The study was performed according to a controlled, randomized and blinded design in a Greek swine unit with Enzootic Pneumonia (EP) and subclinical PCV2 infection. In total, 600 healthy three-week-old suckling piglets were allocated randomly, either to treatment (vaccinated with the test product) or control group (injected with sterile buffered saline).

Results: Vaccination significantly reduced the severity of lung lesions at slaughter (lesions of cranio-ventral pulmonary consolidation) (P&nbsp;&lt;&nbsp;0.001). The overall mean lung lesion score (LLS) was 9.6 in the vaccinated group and 12.2 in controls. The level of PCV2 viraemia was significantly reduced in vaccinated pigs. Furthermore, 25&nbsp;g higher average daily weight gain (ADWG) was observed during the finishing phase (P&nbsp;&lt;&nbsp;0.001) and 18&nbsp;g greater ADWG overall (P&nbsp;&lt;&nbsp;0.001).

Conclusions: Results of LLS, PCV2 viremia and ADWG support the test product&rsquo;s efficacy in the face of strong maternally derived PCV2 immunity.

No MeSH data available.


Related in: MedlinePlus